Amy Sarah Ginsburg

Dr. Amy Sarah Ginsburg

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2015 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SHSaee Hamine
Saee Hamine
EGEmily Gerth-Guyette
Emily Gerth-Guyette
DFDunia Faulx
Dunia Faulx
BGBeverly B Green
Beverly B Green
AGAmy Sarah Ginsburg
Amy Sarah Ginsburg
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

1 December 2020 in The Lancet Global Health
Verified
Journal Article
Open access
AGAmy Sarah Ginsburg
Amy Sarah Ginsburg
KKKeith P Klugman
Keith P Klugman

27 February 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AGAmy Sarah Ginsburg
Amy Sarah Ginsburg
ZLZylee Liddy
Zylee Liddy
PKParsa T. Khazaneh
Parsa T. Khazaneh
SMSusanne May
Susanne May
FPFarhan Pervaiz
Farhan Pervaiz
Point-of-care ultrasound has the potential to help inform assessment, diagnosis, and management of illness in low- and middle-income countries (LMIC). To better understand current ultrasound use, barriers and facilitators to use, and perceptions and practices in LMIC, we conducted an anonymous online global survey targeting healthcare providers training and using ultrasound in LMIC. A total of 241 respondents representing 62 countries participated and most were physicians working in publicly-funded urban tertiary hospitals in LMIC. Most had received ultrasound training (78%), reported expertise (65%) and confidence (90%) in ultrasound use, and had access to ultrasound (88%), utilizing ultrasound most commonly for procedures and for evaluations of lungs, heart, and trauma. Access to an ultrasound machine was reported as both the top barrier (17%) and top facilitator (53%); other common barriers included access to education and training, cost, and competition for use and other common facilitators included access to a probe, gel, and electricity, and acceptance by healthcare providers, administrators, and patients. Most (80%) noted ultrasound access was important and 96% agreed that ultrasound improves quality of care and patient outcomes. Improving access to low-cost ultrasound equipment is critical to increasing ultrasound use among those who are trained.

2 July 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AGAmy Sarah Ginsburg
Amy Sarah Ginsburg
TMTisungane Mvalo
Tisungane Mvalo
ENEvangelyn Nkwopara
Evangelyn Nkwopara
EMEric D. McCollum
Eric D. McCollum
MPMelda Phiri
Melda Phiri
SMSusanne May
Susanne May
Evidence regarding the appropriate duration of treatment with antibiotic agents in children with pneumonia in low-resource settings in Africa is lacking. We conducted a double-blind, randomized, controlled, noninferiority trial in Lilongwe, Malawi, to determine whether treatment with amoxicillin for 3 days is less effective than treatment for 5 days in children with chest-indrawing pneumonia (cough lasting <14 days or difficulty breathing, along with visible indrawing of the chest wall with or without fast breathing for age). Children not infected with human immunodeficiency virus (HIV) who were 2 to 59 months of age and had chest-indrawing pneumonia were randomly assigned to receive amoxicillin twice daily for either 3 days or 5 days. Children were followed for 14 days. The primary outcome was treatment failure by day 6; noninferiority of the 3-day regimen to the 5-day regimen would be shown if the percentage of children with treatment failure in the 3-day group was no more than 1.5 times that in the 5-day group. Prespecified secondary analyses included assessment of treatment failure or relapse by day 14. From March 29, 2016, to April 1, 2019, a total of 3000 children underwent randomization: 1497 children were assigned to the 3-day group, and 1503 to the 5-day group. Among children with day 6 data available, treatment failure had occurred in 5.9% in the 3-day group (85 of 1442 children) and in 5.2% (75 of 1456) in the 5-day group (adjusted difference, 0.7 percentage points; 95% confidence interval [CI], −0.9 to 2.4) — a result that satisfied the criterion for noninferiority of the 3-day regimen to the 5-day regimen. Among children with day 14 data available, 176 of 1411 children (12.5%) in the 3-day group and 154 of 1429 (10.8%) in the 5-day group had had treatment failure by day 6 or relapse by day 14 (between-group difference, 1.7 percentage points; 95% CI, −0.7 to 4.1). The percentage of children with serious adverse events was similar in the two groups (9.8% in the 3-day group and 8.8% in the 5-day group). In HIV-uninfected Malawian children, treatment with amoxicillin for chest-indrawing pneumonia for 3 days was noninferior to treatment for 5 days. (Funded by the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT02678195.)

1 January 2019 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
AGAmy Sarah Ginsburg
Amy Sarah Ginsburg
TMTisungane Mvalo
Tisungane Mvalo
ENEvangelyn Nkwopara
Evangelyn Nkwopara
EMEric D. McCollum
Eric D. McCollum
CNChifundo B. Ndamala
Chifundo B. Ndamala
SMSusanne May
Susanne May
Approximately 920 000 children die of pneumonia annually before their fifth birthday.1 There is a critical need to provide greater access to appropriate and effective treatment. Treatment of bacterial pneumonia requires an effective antibiotic used in adequate doses for an appropriate duration. A 3-day course of twice-daily amoxicillin is recommended by the World Health Organization (WHO) as first-line treatment of nonsevere fast-breathing pneumonia among immune-competent children aged 5 years or less.2 The WHO’s integrated management of childhood illness (IMCI) guidelines identify fast-breathing pneumonia in children with cough or difficult breathing who demonstrate fast breathing without WHO danger signs.3 However, not all cases of fast breathing are bacterial pneumonia. Indeed, the majority of fast-breathing pneumonia cases are likely not pneumonia at all. There are many reasons that a child might demonstrate fast breathing, and not all indicate disease.4-7 Thus, isolated fast breathing may not be appropriately sensitive nor specific for diagnosing pneumonia,8 making antibiotic treatment unnecessary. Although it is relatively well tolerated among children, amoxicillin has side effects and causes serious but rare adverse events.9 Furthermore, inappropriate antibiotic use may lead to antibiotic resistance.10-15

27 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGAmy Sarah Ginsburg
Amy Sarah Ginsburg
CACharlotte Tawiah Agyemang
Charlotte Tawiah Agyemang
GAGwen Ambler
Gwen Ambler
JDJaclyn Delarosa
Jaclyn Delarosa
WBWaylon Brunette
Waylon Brunette
RARichard Anderson
Richard Anderson
Pneumonia is the leading cause of infectious disease mortality in children. Currently, health care providers (HCPs) are trained to use World Health Organization Integrated Management of Childhood Illness (IMCI) paper-based protocols and manually assess respiratory rate to diagnose pneumonia in low-resource settings (LRS). However, this approach of relying on clinical signs alone has proven problematic. Hypoxemia, a diagnostic indicator of pneumonia severity associated with an increased risk of death, is not assessed because pulse oximetry is often not available in LRS. To improve HCPs’ ability to diagnose, classify, and manage pneumonia and other childhood illnesses, “mPneumonia” was developed. mPneumonia is a mobile health application that integrates a digital version of the IMCI algorithm with a software-based breath counter and a pulse oximeter. A design-stage qualitative pilot study was conducted to assess feasibility, usability, and acceptability of mPneumonia in six health centers and five community-based health planning and services centers in Ghana. Nine health administrators, 30 HCPs, and 30 caregivers were interviewed. Transcribed interview audio recordings were coded and analyzed for common themes. Health administrators reported mPneumonia would be feasible to implement with approval and buy-in from national and regional decision makers. HCPs felt using the mPneumonia application would be feasible to integrate into their work with the potential to improve accurate patient care. They reported it was “easy to use” and provided confidence in diagnosis and treatment recommendations. HCPs and caregivers viewed the pulse oximeter and breath counter favorably. Challenges included electricity requirements for charging and the time needed to complete the application. Some caregivers saw mPneumonia as a sign of modernity, increasing their trust in the care received. Other caregivers were hesitant or confused about the new technology. Overall, this technology was valued by users and is a promising innovation for improving quality of care in frontline health facilities.